Biology of gliomas;Biologie des gliomes cérébraux

Cancer/Radiotherapie

Volumn 12, Issue 6-7, 2008, Pages 663-668

  Ducray, F ^a,b,c  

^a HÔPITAL NEUROLOGIQUE   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Angiogenesis; Cancer stem cell; Glioma; Oncogenesis

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ANGIOGENESIS; BIOINFORMATICS; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STEM CELL; CARCINOGENESIS; CELL INFILTRATION; CELL PROLIFERATION; CHROMOSOME 1P; CYTOLOGY; GENE DELETION; GENE MUTATION; GENETIC MODEL; GENOMICS; GLIOMA; HUMAN; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; SHORT SURVEY;

BRAIN NEOPLASMS; CELL CYCLE; CELL DIVISION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PERIPHERAL NERVOUS SYSTEM NEOPLASMS;

EID: 55649091015     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2008.09.001     Document Type: Short Survey

References (54)

1. Aldape K., Burger P.C., and Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131 (2007) 242-251
2. Bagchi A., Papazoglu C., Wu Y., Capurso D., Brodt M., Francis D., et al. CHD5 is a tumor suppressor at human 1p36. Cell 128 (2007) 459-475
3. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
4. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66 (2006) 7843-7848
5. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
6. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008) 592-603
7. Brandes A.A., Franceschi E., Tosoni A., Blatt V., Pession A., Tallini G., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26 (2008) 2192-2197
8. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11 (2007) 69-82
9. Ducray F., Honnorat J., and Lachuer J. DNA microarray technology: principles and applications to the study of neurological disorders. Rev Neurol (Paris) 163 (2007) 409-420
10. Ducray F., Idbaih A., de Reynies A., Bieche I., Thillet J., Mokhtari K., et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 7 (2008) 41
11. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
12. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007) 273-286
13. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21 (2007) 2683-2710
14. Gallia G.L., Rand V., Siu I.M., Eberhart C.G., James C.D., Marie S.K., et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4 (2006) 709-714
15. Gilbert M.R., and Lang F.F. Management of patients with low-grade gliomas. Neurol Clin 25 (2007) 1073-1088
16. Gilbertson R.J., and Rich J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7 (2007) 733-736
17. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
18. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100 (2003) 15178-15183
19. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
20. Idbaih A., Kouwenhoven M., Jeuken J., Carpentier C., Gorlia T., Kros J.M., et al. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. Neuropathology (2008)
21. Idbaih A., Marie Y., Lucchesi C., Pierron G., Manie E., Raynal V., et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 122 (2008) 1778-1786
22. Idbaih A., Marie Y., Pierron G., Brennetot C., Hoang-Xuan K., Kujas M., et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58 (2005) 483-487
23. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
24. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
25. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., and Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 8 (2007) 610-622
26. Jenkins R.B., Blair H., Ballman K.V., Giannini C., Arusell R.M., Law M., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66 (2006) 9852-9861
27. Joy A.M., Beaudry C.E., Tran N.L., Ponce F.A., Holz D.R., Demuth T., et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116 (2003) 4409-4417
28. Lamszus K., Kunkel P., and Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 88 (2003) 169-177
29. Lee J.C., Vivanco I., Beroukhim R., Huang J.H., Feng W.L., DeBiasi R.M., et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3 (2006) e485
30. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5 (2006) 67
31. Louis D.N. Molecular pathology of malignant gliomas. Annu Rev Pathol 1 (2006) 97-117
32. Louis D.N., Holland E.C., and Cairncross J.G. Glioma classification: a molecular reappraisal. Am J Pathol 159 (2001) 779-786
33. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 (2007) 97-109
34. Maher E.A., Brennan C., Wen P.Y., Durso L., Ligon K.L., Richardson A., et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 66 (2006) 11502-11513
35. Marie Y., Carpentier A.F., Omuro A.M., Sanson M., Thillet J., Hoang-Xuan K., et al. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64 (2005) 1444-1445
36. Mischel P.S., Cloughesy T.F., and Nelson S.F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 5 (2004) 782-792
37. Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26 (2008) 3015-3024
38. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
39. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 25 (2005) 1-7
40. Paus C., Murat A., Stupp R., Regli L., and Hegi M. Role of MGMT and clinical applications in brain tumours. Bull Cancer 94 (2007) 769-773
41. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006) 157-173
42. Piccirillo S.G., Reynolds B.A., Zanetti N., Lamorte G., Binda E., Broggi G., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444 (2006) 761-765
43. Reardon D.A., Desjardins A., Rich J.N., and Vredenburgh J.J. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol (2008)
44. Samuels Y., and Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 (2004) 1221-1224
45. Sanson M., Thillet J., and Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 16 (2004) 607-613
46. Sathornsumetee S., Rich J.N., and Reardon D.A. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin 25 (2007) 1111-1139
47. Sauvageot C.M., Kesari S., and Stiles C.D. Molecular pathogenesis of adult brain tumors and the role of stem cells. Neurol Clin 25 (2007) 891-924
48. Shirahata M., Iwao-Koizumi K., Saito S., Ueno N., Oda M., Hashimoto N., et al. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 13 (2007) 7341-7356
49. Singh S.K., Clarke I.D., Hide T., and Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene 23 (2004) 7267-7273
50. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63 (2003) 5821-5828
51. Smith J.S., Chang E.F., Lamborn K.R., Chang S.M., Prados M.D., Cha S., et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26 (2008) 1338-1345
52. Stiles C.D., and Rowitch D.H. Glioma stem cells: a midterm exam. Neuron 58 (2008) 832-846
53. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007) 287-290
54. van den Bent M.J. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 25 (2007) 1089-1109